window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 31, 2026

  • News
  • About Us
Contact Us

Regulatory Affairs

  • Biomanufacturing,CDMOs & Manufacturing,Movers & Shakers,Regulatory Affairs,Technology and platforms

    Spore.Bio appoints Michael Miller as VP of scientific and regulatory affairs

    Spore.Bio has appointed Michael Miller as vp of scientific and [...]

    January 30, 2026
  • Digital Health,Healthcare leadership,Medical devices,Mental health,Regulatory Affairs

    Mental health systems strain as demand and funding shifts drive push for multimodal care

    Mental health systems in the US and UK have entered [...]

    January 29, 2026
  • Biotech,Clinical Trials,Funding,Regulatory Affairs

    MaaT Pharma reports H1 2025 results and advances Xervyteg regulatory pathway

    MaaT Pharma has reported its half year 2025 financial results, [...]

    January 26, 2026
  • Drug approval,Immunology,Pharmaceuticals and therapeutics,Rare Diseases,Regulatory Affairs,RNA Therapeutics

    Donidalorsen granted EU approval for hereditary angioedema prevention

    Donidalorsen has received European Union marketing authorisation for the routine [...]

    January 23, 2026
  • Biomanufacturing,CDMOs & Manufacturing,Regulatory Affairs,Supply Chain & Logistics

    Drug Association to host sustainable packaging innovation workshop at Pharmapack Europe 2026

    The Parenteral Drug Association will host a half-day workshop focused [...]

    January 21, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Regulatory Affairs

    Accord Healthcare disappointed as people with ES-SCLC in Scotland denied access to serplulimab

    Patients in Scotland living with extensive-stage small cell lung cancer [...]

    January 23, 2026
  • Biotech,Rare Diseases,Regulatory Affairs,Research & Development

    Minovia secures two new US patents for mitochondrial augmentation therapy platform

    Minovia Therapeutics has been granted two new US patents covering [...]

    January 13, 2026
  • Clinical Development,Clinical Trials,Drug approval,Oncology,Pharmaceuticals and therapeutics,Rare Diseases,Regulatory Affairs

    FDA accepts Merck NDA for pimicotinib in tenosynovial giant cell tumor

    Merck has announced that the US Food and Drug Administration [...]

    January 13, 2026
  • CDMOs & Manufacturing,Cell & Gene Therapy,Clinical Development,Clinical Trials,Regulatory Affairs

    FDA clears IND amendment for automated manufacturing of Cabaletta’s rese-cel using Cellares platforms

    Cellares has secured FDA clearance of an IND amendment allowing [...]

    January 13, 2026
  • Clinical Development,Clinical studies,Clinical Trials,Data Management,Digital Health,Drug Development,Regulatory Affairs,Technology and platforms

    CluePoints: how proactive oversight and AI are reshaping clinical trial data management

    Dan Beaudry, market owner for risk-based quality management (RBQM) at [...]

    January 7, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Evestia Clinical acquires ICRC-Weyer to expand full-service clinical research in Europe
    Categories: Biotech, CDMOs & Manufacturing, Clinical Development, Clinical Trials, Partnerships & Funding
  • Mental health systems strain as demand and funding shifts drive push for multimodal care
    Categories: Digital Health, Healthcare leadership, Medical devices, Mental health, Regulatory Affairs
  • Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer
    Categories: Clinical studies, Drug Development, Oncology, Precision medicine, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top